1seq
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1seq.gif|left|200px]] | [[Image:1seq.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1seq", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | | | + | or leave the SCENE parameter empty for the default display. |
| - | | | + | --> |
| - | + | {{STRUCTURE_1seq| PDB=1seq | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Fab MNAC13''' | '''Fab MNAC13''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | + | Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1SEQ OCA]. | |
==Reference== | ==Reference== | ||
Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight., Covaceuszach S, Cattaneo A, Lamba D, Proteins. 2005 Feb 15;58(3):717-27. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15625712 15625712] | Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight., Covaceuszach S, Cattaneo A, Lamba D, Proteins. 2005 Feb 15;58(3):717-27. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15625712 15625712] | ||
| - | [[Category: Mus musculus]] | ||
| - | [[Category: Protein complex]] | ||
[[Category: Cattaneo, A.]] | [[Category: Cattaneo, A.]] | ||
[[Category: Covaceuszach, S.]] | [[Category: Covaceuszach, S.]] | ||
[[Category: Lamba, D.]] | [[Category: Lamba, D.]] | ||
| - | [[Category: | + | [[Category: Immunoglobulin]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 08:36:53 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 05:36, 3 May 2008
Fab MNAC13
Overview
MNAC13, a mouse monoclonal antibody, recognizes with high affinity and specificity the neurotrophin receptor TrkA and displays a neutralizing activity toward the NGF/TrkA interaction. Detailed knowledge of the molecular basis determining the specificity of this antibody is of importance because of its potential use as a modulator of the TrkA-mediated NGF activity. Here, we report a full biochemical and structural characterization of the MNAC13 antibody. Epitope mapping studies, by serial deletion mutants and by phage display, reveal a conformational epitope that is localized on the carboxy-terminal region of the first immunoglobulin-like domain (d4) of TrkA. The X-ray crystal structure of the MNAC13 Fab fragment has been determined and refined to 1.8 A resolution. The antigen-binding site is characterized by a crevice, surrounded by hydrophilic-charged residues on either side, dipping deep toward three mainly hydrophobic subsites. Remarkably an isopropanol molecule has been found to bind in one of the hydrophobic crevices. Overall, the surface topology (shape and electrostatic potential) of the combining site is consistent with the binding data on TrkA ECD serial deletions mutants. The structure of the MNAC13 Fab fragment may assist in the rational structure-based design of high affinity humanized forms of MNAC13, appropriate for therapeutic approaches in neuropathy and inflammatory pain states.
About this Structure
Full crystallographic information is available from OCA.
Reference
Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight., Covaceuszach S, Cattaneo A, Lamba D, Proteins. 2005 Feb 15;58(3):717-27. PMID:15625712 Page seeded by OCA on Sat May 3 08:36:53 2008
